Ascendis Pharma ADR saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 71 to 82.
IBD's unique RS Rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Ascendis Pharma ADR is trying to complete a consolidation with a 161.00 entry. See if it can break out in volume at least 40% above average.
Ascendis Pharma ADR showed 0% EPS growth in its most recent report, while sales growth came in at 18%.
The company earns the No. 36 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics, Corcept Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
